{'output': [['PTC Therapeutics, Inc.', 'COMP', 'Provide', 'Corporate Update', 'EVENT'], ['Stuart W. Peltz, Ph.D.', 'PERSON', 'Highlight', 'Companys Presentation', 'EVENT'], ['PTC Therapeutics, Inc.', 'COMP', 'Operate_In', 'NASDAQ', 'ORG/REG'], ['Translarna™', 'PRODUCT', 'Treat', 'Nonsense Mutation Duchenne Muscular Dystrophy', 'CONCEPT'], ['Translarna™', 'PRODUCT', 'Achieve', 'Upper End of Guidance', 'CONCEPT'], ['Translarna™', 'PRODUCT', 'Net Product Revenue', '145 Million', 'ECON_INDICATOR'], ['EMFLAZA™', 'PRODUCT', 'Treat', 'Duchenne Muscular Dystrophy', 'CONCEPT'], ['EMFLAZA™', 'PRODUCT', 'Net Product Revenue', '29 Million', 'ECON_INDICATOR'], ['PTC Therapeutics, Inc.', 'COMP', 'Anticipate', 'Full-Year Net Product Revenues', 'CONCEPT'], ['PTC Therapeutics, Inc.', 'COMP', 'Anticipate', 'Translarna Net Product Revenue', 'CONCEPT'], ['PTC Therapeutics, Inc.', 'COMP', 'Project', '5-Year Compound Annual Growth Rate', 'CONCEPT'], ['PTC Therapeutics, Inc.', 'COMP', 'Anticipate', 'EMFLAZA Net Product Revenue', 'CONCEPT'], ['PTC Therapeutics, Inc.', 'COMP', 'Anticipate', 'GAAP R&D and SG&A Expense', 'CONCEPT'], ['PTC Therapeutics, Inc.', 'COMP', 'Anticipate', 'Non-GAAP R&D and SG&A Expense', 'CONCEPT'], ['PTC Therapeutics, Inc.', 'COMP', 'Plan', 'Continued Growth of Translarna Product Revenue', 'CONCEPT'], ['PTC Therapeutics, Inc.', 'COMP', 'Expand', 'Innovative Pipeline', 'CONCEPT'], ['PTC Therapeutics, Inc.', 'COMP', 'Host', 'Analyst Day', 'EVENT'], ['PTC Therapeutics, Inc.', 'COMP', 'Use', 'Non-GAAP Financial Measures', 'CONCEPT'], ['PTC Therapeutics, Inc.', 'COMP', 'Assess', 'Operational Trends', 'CONCEPT'], ['PTC Therapeutics, Inc.', 'COMP', 'Identify', 'Operational Trends', 'CONCEPT'], ['PTC Therapeutics, Inc.', 'COMP', 'Exclude', 'Non-Cash Stock-Based Compensation Expense', 'CONCEPT']]}